| __timestamp | Amphastar Pharmaceuticals, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 15746000 |
| Thursday, January 1, 2015 | 46974000 | 13392000 |
| Friday, January 1, 2016 | 47298000 | 9290000 |
| Sunday, January 1, 2017 | 50918000 | 7672000 |
| Monday, January 1, 2018 | 58044000 | 15293000 |
| Tuesday, January 1, 2019 | 63109000 | 22648000 |
| Wednesday, January 1, 2020 | 65157000 | 21864000 |
| Friday, January 1, 2021 | 68920000 | 37318000 |
| Saturday, January 1, 2022 | 66592000 | 48130000 |
| Sunday, January 1, 2023 | 80393000 | 108146000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and Madrigal Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amphastar's SG&A expenses grew steadily, peaking at approximately 80 million in 2023, marking a 99% increase from 2014. In contrast, Madrigal's SG&A expenses skyrocketed by over 587% during the same period, reaching around 108 million in 2023. This dramatic rise reflects Madrigal's aggressive expansion and investment strategies. While Amphastar maintained a consistent growth rate, Madrigal's spending surged, particularly post-2020, indicating a strategic pivot. These trends highlight the diverse approaches companies take in managing operational costs, with Madrigal's rapid increase suggesting a focus on scaling operations and market presence.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE